Krystal Biotech Inc

Healthcare · Biotechnology

345.80$ +0.2% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Krystal Biotech Inc (KRYS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,501 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet KRYS
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	2.2	2.2	4.0	53	50	48	46	54	116	116	205	214	209	205	318	311	311	443	444	451	626	617	601	576	558	532	684	790	818	853	918	982	1,056	1,074	1,138	1,240	1,334	1,397	1,501
Current Assets	–	2.2	2.1	3.9	53	50	48	46	53	113	108	196	204	196	188	299	288	275	406	370	346	442	438	429	398	384	355	484	582	588	602	683	713	742	767	841	926	1,025	1,020	1,060
Cash	–	1.9	2.0	3.5	53	50	47	42	47	104	98	187	195	188	180	292	282	268	402	330	287	341	269	219	186	162	141	276	373	358	359	346	374	345	309	354	393	496	501	428
Cash & Short-Term Investments	–	1.9	2.0	3.5	53	50	47	45	52	112	107	195	203	194	187	297	286	271	403	368	343	438	435	426	394	379	350	478	562	532	538	560	588	598	617	682	731	828	823	846
Receivables	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	–	–	9.3	42	46	103	97	105	103	111	130	127	127	139
Inventory	–	–	–	–	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	–	–	5.3	7.0	11	12	19	27	30	31	38	40	43	46
Property, Plant & Equipment	–	0.0	0.0	0.0	0.1	0.2	0.2	0.3	1.6	3.0	7.4	8.9	9.7	11	13	16	18	31	34	52	86	120	137	159	158	170	163	164	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	–	1.9	2.3	0.6	2.5	0.6	0.5	0.8	2.2	2.9	6.2	6.9	6.6	6.1	6.8	8.4	9.7	19	12	25	43	33	68	42	36	36	42	31	34	40	54	79	96	109	90	98	102	114	120	142
Current Liabilities	–	0.0	0.1	0.6	2.5	0.6	0.5	0.8	1.9	2.6	3.2	3.9	3.7	3.3	4.1	5.8	7.2	15	9.1	18	36	26	60	34	28	29	35	24	28	33	48	72	90	102	79	87	91	103	108	127
Short-Term Debt	–	1.8	2.1	4.1	–	–	–	–	–	–	0.4	0.4	0.5	0.5	0.5	0.5	0.6	8.2	0.6	0.9	1.0	1.0	1.4	1.4	1.5	1.6	1.6	1.5	1.5	1.5	1.4	1.4	1.3	1.2	1.4	1.6	1.7	1.8	1.8	1.8
Accounts Payable	–	0.0	0.1	0.3	0.6	0.2	0.1	0.2	0.4	0.9	1.1	0.9	1.3	1.0	0.6	1.6	2.6	2.1	1.8	1.3	4.8	8.4	8.2	9.2	5.8	4.0	4.1	4.4	4.3	4.1	5.4	5.4	5.6	5.0	2.7	7.1	2.1	3.2	4.1	6.5
Long-Term Debt	–	1.8	2.1	–	0.0	0.0	0.0	0.0	0.0	–	3.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	–	0.3	-0.1	3.4	50	49	47	45	52	113	109	198	208	203	198	310	302	292	431	419	408	594	549	559	541	522	490	653	756	779	799	839	886	946	985	1,041	1,138	1,220	1,277	1,359
Retained Earnings	–	-1.2	-1.6	-5.5	-7.7	-9.1	-11	-13	-16	-20	-24	-29	-34	-39	-44	-51	-61	-71	-87	-103	-119	-141	-191	-219	-249	-281	-326	-359	-279	-270	-269	-253	-226	-181	-145	-107	-27	24	80	135
Shares Outstanding	4.3	4.3	4.3	8.7	4.2	10	10	10	11	14	14	15	17	17	17	18	20	20	21	22	22	22	25	26	26	26	26	27	29	29	29	30	30	30	30	30	30	30	31	31

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings